Harvard Bioscience (HBIO) Liabilities and Shareholders Equity (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $77.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $77.9 million, down 2.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $316.1 million (down 32.26% YoY), and the FY2025 annual result was $80.1 million, down 36.77% from the prior year.
• Liabilities and Shareholders Equity retreated to $77.9 million in Q1 2026 per HBIO's latest filing, from $80.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $158.0 million in Q1 2022 and troughed at $77.9 million in Q1 2026.
• A 5-year average of $122.8 million and a median of $133.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity increased 4.49% in 2022, then tumbled 40.57% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $145.4 million in 2022, then decreased by 5.5% to $137.4 million in 2023, then retreated by 7.81% to $126.6 million in 2024, then sank by 36.77% to $80.1 million in 2025, then decreased by 2.66% to $77.9 million in 2026.
• Business Quant data shows HBIO's Liabilities and Shareholders Equity at $77.9 million in Q1 2026, $80.1 million in Q4 2025, and $78.0 million in Q3 2025.